Seer board rejects upgraded $2.35-a-share take-private bid from Radoff-JEC Group

11 articles · Updated · MarketWatch · Apr 27

The board unanimously dismissed the revised offer from minority shareholders Bradley Radoff and Michael Torok, who collectively own about 7.6% of Seer's shares.
The latest proposal included a contingent value right and was increased from an earlier $2.25 per share bid submitted on April 13.
Seer’s board maintains confidence in its current strategy, platform, and team to deliver greater value, as shares have risen 7.7% year-to-date and last closed at $1.97.

Seer's board rejected a premium offer. What is its hidden plan to create superior shareholder value?

After two rejections, what is the activist investors' next move to force a sale of Seer?

Beyond the buyout drama, is Seer's proteomics technology the real prize investors are missing?

With cash dwindling and no profits until 2031, can Seer justify rejecting a concrete buyout offer?

Now that Seer is clearly in play, will a larger pharma company swoop in with a knockout bid?

The CEO sold stock yet rejects a buyout. How does the board justify this leadership contradiction?